BridgeBio Pharma, Inc. (BBIO): Total Liabilities
$3.01B
As of 2025-12-31
$3.72B
As of 2026-06-30
+17.3%
3-year compound annual growth
+38.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.01B | +26.7% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $2.38B | +25.8% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $1.89B | +1.1% | 2025-02-20, Balance as of period end |
| 2022-12-31 | $1.87B | -0.6% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $1.88B | +215.3% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $595.70M | +282.6% | 2022-02-25, Balance as of period end |
| 2019-12-31 | $155.70M | +77.8% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $87.58M | n/a | 2020-03-03, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $3.01B | +26.7% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $490.36M | -8.4% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $528.12M | +18.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $501.83M | -0.1% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $456.88M | +32.5% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $164.81M | +46.4% |
| Insmed Inc (INSM) | 2025-12-31 | $1.53B | -12.3% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $663.99M | -20.5% |
Compare BBIO, TVTX, MIRM, NATR side by side · Screen every company in Pharmaceutical Preparations ↗